Table 2: Biological drugs targeting molecules relevant for atopic/allergic disease pathomechanisms.                                                                                                                                                                    
Target Indication Drug  
IL-5 receptor (CD125) Asthma Benralizumab  
Inhibits the dimerization of IL-13Rα1 and IL-4Rα Asthma + AD Lebrikizumab *
IL-5 Asthma Mepolizumab  
IL-5 Rα Asthma Reslizumab  
IgE Asthma + Urticaria Omalizumab  
IL-4 Rα subunit AD, Asthma, CRSwNP Dupilumab  
IL-9 Asthma Enokizumab *
IL-13 AD Tralokinumab  
IL-33 AD Etokimab  
IL-31 receptor A AD Nemolizumab  
TSLP Tezepelumab Tezepelumab  
IgE Chronic urticaria Ligelizumab  
IgE Chronic urticaria, Asthma, CRSwNP Omalizumab  
Lectin 8 Asthma Lirentelimab  
Inhibits JAK1 and JAK2 AD Baricitinib  
JAK1 inhibitor AD Upadacitinib  
JAK1 inhibitor AD Abrocitinib  
A CRTH2 antagonist Th2-mediated inflammation AMG853 *
A CRTH2 antagonist Th2-mediated inflammation OC000459 *
A CRTH2 antagonist Th2-mediated inflammation BI671800 *
Inhibitor of GSNOR Th2-mediated inflammation N6022 *
Plasma kallikrein Hereditary angioedema Lanadelumab  
Adapted from Guelsen et al., 202030, modified and updated 31. *Studies ongoing